×

[Seminar] Acute respiratory distress syndrome

Acute respiratory distress syndrome presents as hypoxia and bilateral pulmonary infiltrates on chest imaging in the absence of heart failure sufficient to account for this clinical state. Management is largely supportive, and is focused on protective mechanical ventilation and the avoidance of fluid overload. Patients with severe hypoxaemia can be managed with early short-term use of neuromuscular blockade, prone position ventilation, or extracorporeal membrane oxygenation. The use of inhaled nitric oxide is rarely indicated and both β2 agonists and late corticosteroids should be avoided.

[Department of Error] Department of Error

MacSweeney R, McAuley DF. Acute respiratory distress syndrome. Lancet 2016; 388: 2416–30—In the “Oxygenation (mm Hg)” row of the “Berlin, 2012” column in the table of this Seminar, the data were incorrectly listed as PaO2—they should have been PaO2/FiO2. This correction has been made to the online version as of Nov 10, 2016, and the printed Seminar is correct.

[Interactive Grand Round] Severe respiratory failure

A 41-year-old man presents with flu-like symptoms and severe respiratory distress. What are the management priorities? What techniques can be used to manage his respiratory failure? Despite optimal respiratory management the patient’s condition deteriorated, and he developed a troponin rise that remained static, associated with regional wall motion abnormalities on echocardiography. What cardiac imaging tests would best identify the potential aetiology?

GPs targeted in national plan to curb antibiotic resistance

GPs will be targeted over their antibiotic prescription practices as part of a national strategy to tackle the threat from rising antibiotic resistance.

Less than 10 days after researchers sounded the alarm over the arrival in Australia of a superbug capable of overcoming the last line of defence against salmonella infection, the Federal Government has detailed its plans to implement the National Antibiotic Resistance Strategy.

Health Minister Sussan Ley said the inaugural plan, covering the period 2015-19, had as one of its main targets reduced recourse to antibiotics by GPs.

“A particular focus will be Australia’s high use of antibiotics in general practice, which is 20 per cent above the OECD average,” Ms Ley said. “Bringing prescribing rates down is critical, as high antibiotic use is the number one driver of the increasing resistance to antimicrobials.”

Despite this focus Ms Ley, who launched the strategy in conjunction with Agriculture Minister and Deputy Prime Minister Barnaby Joyce, said the plan encompassed a broad “one health” approach which recognised the inextricable links between human, animal and ecosystem health.

“[This means] that combating resistance to antimicrobials requires action in all sectors where antimicrobials are used,” the Health Minister said.

The plan calls for, among other things, better support for doctors and vets in educating patients about the need for care in antibiotic use; the implementation of effective stewardship practices among health professionals; improved national surveillance of antibiotic use; better infection control measures; and intensified research efforts.

The plan has been developed amid mounting international alarm regarding the threat posed by antibiotic resistance. A recent British Government report warned the world was on track to a future in which even common infections and medical procedures could become potentially deadly because of the risk of infection.

The UK report estimated that antimicrobial resistance could kill 10 million a year by 2050, and cost the world a cumulative USD$100 trillion in reduced economic output without effective action to slow the rate of drug resistance.

The threat to Australia has escalated following the discovery by Murdoch University researchers of a strain of the Salmonella bug that is resistant to carbapenems, the drug used as the last line of defence against such infections.

The superbug was discovered in a pet cat admitted to Concord Veterinary Hospital in New South Wales with an upper respiratory tract infection that subsequently developed into a gut infection.

A sample of the infection sent to a team of researchers at the Concord Hospital identified a strain of Salmonella never before seen in the country. It was found to be carrying the highly resistant IMP-4 gene.

A further three animals at the veterinary clinics were also found to be infected with the superbug. The outbreak has been contained.

Dr Abraham said the identification and containment of the bacteria was “an example of Australia’s One Health capabilities, where animal and human health specialists work together to prevent the spread of infection”.

Adrian Rollins

 

[Review] Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action

In China, where air pollution has become a major threat to public health, public awareness of the detrimental effects of air pollution on respiratory health is increasing—particularly in relation to haze days. Air pollutant emission levels in China remain substantially higher than are those in developed countries. Moreover, industry, traffic, and household biomass combustion have become major sources of air pollutant emissions, with substantial spatial and temporal variations. In this Review, we focus on the major constituents of air pollutants and their impacts on chronic respiratory diseases.

New guidelines for asthma treatment

The Australian Asthma Handbook has been updated, providing information about the latest medications for asthma and chronic obstructive pulmonary disease (COPD).

The National Asthma Council Australia developed the handbook with an interdisciplinary team of medical experts, and has incorporated feedback from primary care providers.

National Asthma Council Australia chair Professor Amanda Barnard said the guide would clarify any confusion about asthma and COPD drugs.

“New asthma and COPD drugs have come on the market over the last two years, and doctors have expressed confusion about when to use which medication as well as the long-term safety of various options,” Professor Barnard said.

“The [handbook] provides factual information on all the latest medications, including what conditions they treat, how they differ from existing drugs and clarification of their suitability for long versus short-term use.”

Five updates:

  • Consensus advice against use of e-cigarettes, recommending that people with asthma should be discouraged from using e-cigarettes, even for smoking cessation, until further evidence on the risks is available.
  • Clarification of rationale for long-term use of low-dose inhaled corticosteroids, emphasising that this is the recommended treatment for most adults with asthma and aims to reduce risk of flare-ups, even if day-to-day symptoms are infrequent.
  • Evidence-based advice on the roles and uses of new add-on treatment options, including mepolizumab, omalizumab and tiotropium, plus new specific allergen immunotherapy preparations
  • Update of inhaler technique and spacer priming advice to reflect the Asthma Council’s recent information paper on this topic, noting that most patients do not use inhaler devices correctly, providing guidance on how to improve patient technique, and introducing a new table to help clarify which spacers require priming before first use.
  • Increased emphasis on written asthma action plans, highlighting the central recommendation that every adult and child with asthma should have a personalised written asthma action plan

The council has updated its popular Asthma and COPD Medications wall chart; as well as including all the latest inhalers available in Australia, the updated version specifies each medication’s current PBS reimbursement status for asthma and COPD.

The new Allergic Rhinitis Treatments wall chart has also been developed in the same style. The new chart shows the main intranasal treatment options available in Australia for allergic rhinitis.

Related: Over-the-counter asthma prevention

PDF copies of the Asthma and COPD Medications wall chart and Allergic Rhinitis Treatments wall chart are available here.

The updated Australian Asthma Handbook version 1.2, including a full list of amendments, is available here.

Latest news

Women’s health: local and global matters of great significance

A life cycle approach is important, as is acknowledging the importance of socio-cultural and lifestyle factors

Women’s health, in its broadest sense, encompasses all aspects of their health and wellbeing. From this perspective, this issue of the MJA includes a wide selection of articles covering key issues in women’s health, both locally and globally. The topics covered are diverse, and include pregnancy and reproductive health, as well as health and wellbeing at various stages of a woman’s life cycle. Taking a life course perspective of women’s health clarifies links between their socio-cultural background, reproductive health, lifestyle, and chronic disease risk.1 Significant events across the lifespan, including birthweight and age of menarche, have been identified as likely markers of cardiovascular disease risk,2 pre-menopausal breast cancer risk,3 and diabetes4 in women.

Most women in high and middle income countries will come into contact with health systems and health professionals while they are pregnant, but in Australia there is a confusing plethora of models of care. In some models the care is fragmented, as women move between primary and secondary care, private and public services, and medical and midwifery providers. Outcomes of pregnancy are important indicators of health for women and their families, so it is essential that women have access to a model of care that provides them with the best possible outcomes in every respect.

The narrative review by Homer5 examines the evidence in favour of continuity of care models in which a midwife is the primary maternity caregiver. The evidence, much of which is from Australia, is very clearly in favour of such models. Women report high levels of satisfaction with the midwife’s holistic approach to care during pregnancy and the postnatal period; the maternal and perinatal outcomes are the same as for other medical models, and are achieved with less intervention and at lower cost. The considerable high level evidence from randomised clinical trials now forms the basis of guidelines that advocate this approach for low or normal risk women. Why is it then so difficult for many women to choose this evidence-based model of midwifery care during pregnancy? Only a minority of women can access this form of care, and maternity hospitals appear reluctant to recognise the evidence. Inter-professional rivalries, lack of collaborative leadership models, and inaccurate citing of evidence all block further development, and the translation of the available evidence into practice is held up. As Homer remarks, it really needs to be asked whether it is ethical to deny women access to a model of care that is so strongly supported by the evidence.

Further assessment of how effectively these models work for women with higher risks during pregnancy is required, and one of the greatest challenges is ensuring that all health professionals involved in maternity care work collaboratively to achieve the best outcomes. It makes sense that women at higher psycho-social risk would benefit from greater continuity. Whether or not such models lead to better medium and long term psychological and emotional outcomes for all women needs to be determined, but there is potential for significant benefits for the entire family if the model enhances their wellbeing in the postnatal period and beyond. The likelihood that this outcome of pregnancy will impact on women later in life should be obvious to all.

In their later years, non-communicable diseases (NCDs) pose one of the greatest threats to women’s health globally. NCDs such as cardiovascular disease, cancer, diabetes, and chronic respiratory diseases currently account for around 18 million deaths in women annually, and it is estimated that this will rise by 17% over the next decade.6 The perspective article on global women’s health by Davidson and colleagues7 identifies that much of the increased risk has been attributed to socio-cultural factors, although lifestyle factors, such as unhealthy diet, alcohol consumption and smoking, physical inactivity, and obesity, also play pivotal roles.6 Davidson and colleagues argue that the ramifications of the burden of NCDs for women, their families and the global community is significant, and will lead to escalating health care costs, lost productivity, and adverse social and economic outcomes for families.7

Importantly, the perspective article by Teede and colleagues8 explains how biological differences, gender roles, and social marginalisation affect women, and mean that their risk behaviours are not the same as those of men, with consequences for the success of health-related interventions. From this perspective, more targeted health programs for women and health models of care are likely to better promote the wellbeing of women generally, as well as during pregnancy. This approach should help reduce the impact of modifiable risk factors and the burden of chronic disease, and enhance the development of comprehensive evidence-based policy and practice that improve women’s health.

There is increasing evidence that women’s health needs, both locally and globally, are best served by interventions tailored to their specific needs, acknowledging the links between socio-cultural background, reproductive health, lifestyle and chronic disease risk. Improving health outcomes for women, during pregnancy and at other stages of their life cycle, requires health service providers to recognise this, and to use the evidence to inform their provision of care that is both effective and acceptable to women.

Hospital trial turns night into day for US doctors, patients

Picture: Dr Timothy Buchman talks to a colleague in Atlanta from the ‘Turning Night Into Day’ centre at Macquarie University 

Night has become day for a group of US doctors and critical care nurses, who are using new technology to remotely monitor their intensive care patients in hospitals in Atlanta from a Sydney health campus.

The intensivists and nurses from US health provider Emory Healthcare are part of a clinical trial to assess the health benefits for both patients and doctors of having highly experienced clinicians available to provide senior support around the clock.

Taking advantage of remote intensive care unit (eICU) technology and the 14-hour time difference, the medical teams are essentially working the Atlanta night shift during the day in Sydney.

“We’re in Australia because we are trying to look at a different model of care,” Cheryl Hiddleson, the director of Emory’s eICU Centre, told Australian Medicine.

“We were having our clinicians up all night while they were trying to do other things during the day – that’s just what happens. We know that working the night shift is tough.

“This study is to look at our staff and see how the difference in the times that they are working makes to their performance and their health.”

Under the trial, senior intensivists and critical care nurses from Emory are based in Sydney for six to eight week rotations.

They work at MQ Health at Macquarie University, using eICU technology developed by health technology maker Royal Philips, to provide continuous night-time critical care oversight to high-risk patients in Emory’s six hospitals across the state of Georgia.

“We intensive care folk have one mission, and that’s to deliver the right care for the right patients at the right time,” Dr Timothy Buchman, the chief of Emory’s Critical Care Services, said.

“Almost everything we do has to be done with both speed and care. That’s easy in a big hospital at 10am on a Monday, but that task becomes a lot harder in a remote or rural hospital at unsocial hours – on weekends, holiday, or especially at night.

“There are fewer people, and less experienced people, and patients can become sicker around the clock. Patients and their families deserve the best care, and this is about bringing that senior support to the bedside.”

The day before Dr Buchman spoke to Australian Medicine, he helped treat a patient who had been airlifted to one of Emory’s Atlanta hospitals at 2am US time – 4pm in Sydney.

The patient was suffering severe pancreatitis and respiratory failure, and was being treated by a relatively junior doctor.

“I had a complete echo of the bedside monitor, and was able to guide the doctor through the treatment,” Dr Buchman said.

“The attending physician would have been at home, probably asleep. But I was able to go in as if I was there and help implement care plans.”

Two hours later, another patient came in from a smaller hospital, suffering post-operative haemorrhaging.

“She was deeply anaemic, but she was also a Jehovah’s Witness and so was refusing blood products,” Dr Buchman said.

“The other hospital said we needed experimental therapies, so we accepted her admission. I was able to evaluate her remotely and provide the level of care she needed. When I came in to work this morning, I was able to check on her condition again.”

The previous night, just before 1am, the family of a terminally ill cancer patient, who had been intubated earlier in the day, requested a meeting to evaluate his care.

“I was able to talk to them – they could see me, I could see them – and they decided to shift from aggressive care to comfort,” Dr Buchman said.

“The patient was able to die. His family were able to be there and it was able to occur in a timely fashion. The family had come to a decision and acceptance, and they could have that meeting when they needed it, instead of having to wait for hours.”

Emory already uses the eICU to provide senior support to smaller and remote hospitals throughout Georgia. The time difference trial is intended to see if the technology can help keep senior clinicians in the workforce.

“People do function a lot better when they can do night work in day time,” Dr Buchman said.

“This technology is important, but it is only an enabler. The people – the staff, the patients – are what is important, and this technology gives us the ability to use this accumulated wisdom during daylight for patients on the other side of the world who would not normally have access to this level of expertise.”

Maria Hawthorne

[Correspondence] Low-dose hydrocortisone in extremely preterm infants

The study by Olivier Baud and colleagues1 provides additional insight into the use of hydrocortisone in the prevention of bronchopulmonary dysplasia in premature infants. The large, multicentre, double-blind randomised controlled trial showed that, in extremely preterm infants born before 28 weeks, the rate of survival without bronchopulmonary dysplasia (defined as a requirement for respiratory support and oxygen requirement at 36 weeks of postmenstrual age) was significantly increased by prophylactic low-dose hydrocortisone given in the first 10 days of life.

Australian Burden of Disease Study: impact and causes of illness and death in Aboriginal and Torres Strait Islander people 2011

This report provides estimates of the non-fatal and fatal burden of disease for the Aboriginal and Torres Strait Islander population as well as estimates of the gap in disease burden between Indigenous and non-Indigenous Australians. The disease groups causing the most burden among Indigenous Australians in 2011 were mental and substance use disorders, injuries, cardiovascular diseases, cancer and respiratory diseases. Indigenous Australians experienced a burden of disease that was 2.3 times the rate of non-Indigenous Australians. Over one third of the overall disease burden experienced by Indigenous Australians could be prevented by removing exposure to risk factors such as tobacco and alcohol use, high body mass, physical inactivity and high blood pressure.